ProMark: a first-of-its-kind protein based prognostic test for prostate cancer

Predict cancer aggressiveness* in patients with biopsy Gleason Scores of 3+3 and 3+4.

• Provides a personalized prediction that the cancer can be managed without aggressive treatment, or an indication that aggressive therapy may be appropriate
• Powerful, independent risk predictor for prostate cancer
• Objective and fully reproducible
• Predictive of disease aggressiveness throughout the prostate, reducing sampling error
• Outperforms and requires substantially less tissue than conventional gene-expression-based prostate cancer prognostic tests
• Cutting edge, automated image recognition technology provides objective identification of tumor cells and quantitative measurement of predictive protein biomarker expression levels
• Generates an individual risk score delivered within an intuitive report allowing for productive discussion with your patient
• Specific: Developed exclusively for use on prostate biopsy tissue
• Unique, 8-protein signature
• Strong clinical validation
• Included in the NCCN Clinical Care Guidelines